Companies / Health Care
DHR
Danaher Corporation
Life Sciences Tools & Services
Life Sciences Tools & ServicesAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health71
Growth26
Profitability66
Cash generation93
Balance sheet73
Dilution control98
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-25)8.3%Revenue growth (FY)2.9%Revenue CAGR (3y)-2.7%Gross margin59.1%Operating margin19.1%Net margin14.7%Free cash flow margin21.4%R&D / revenue6.5%Stock comp / revenue1.2%Net debt / operating cash flow2.15xCurrent ratio1.87Diluted share count change-2.9%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $24.8B | $26.6B | $23.9B | $23.9B | $24.6B |
| Gross profit | $15.2B | $16.2B | $14.0B | $14.2B | $14.5B |
| Operating income | $6.4B | $7.5B | $5.2B | $4.9B | $4.7B |
| Net income | $6.4B | $7.2B | $4.8B | $3.9B | $3.6B |
| Operating cash flow | $8.4B | $8.5B | $7.2B | $6.7B | $6.4B |
| Capital expenditure | $1.2B | $1.1B | $1.4B | $1.4B | $1.2B |
| Free cash flow | $7.1B | $7.4B | $5.8B | $5.3B | $5.3B |
| R&D | $1.5B | $1.5B | $1.5B | $1.6B | $1.6B |
| Stock-based comp | $184M | $295M | $306M | $288M | $298M |
| Buybacks | — | $0 | $0 | $6.0B | $3.1B |
| Dividends | $742M | $818M | $821M | $768M | $878M |
| Cash | $2.6B | $6.0B | $5.9B | $2.1B | $4.6B |
| Total debt | $22.2B | $20.3B | $20.1B | $16.5B | $18.4B |
| Equity | $45.2B | $50.1B | $53.5B | $49.5B | $52.5B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.